Valuation: Lyell Immunopharma, Inc.

Market Cap 268M 240M 222M 201M 376M 25.51B 380M 2.66B 1.06B 13.35B 1.01B 984M 42.38B P/E 2026 *
-1.51x
P/E 2027 * -1.42x
Enterprise Value 171M 153M 142M 128M 240M 16.27B 243M 1.69B 675M 8.51B 641M 628M 27.03B EV / Sales 2026 *
14,381x
EV / Sales 2027 * 24,220x
Free-Float
60.75%
Yield 2026 *
-
Yield 2027 * -
1 day+4.99%
1 week+23.56%
Current month+18.39%
1 month+20.35%
3 months-10.64%
6 months-43.74%
Current year-62.35%
1 week 9.05
Extreme 9.05
11.59
1 month 7.2
Extreme 7.195
11.59
Current year 7.2
Extreme 7.195
31.32
1 year 7.2
Extreme 7.195
45
3 years 7.2
Extreme 7.195
65.11
5 years 7.2
Extreme 7.195
309.9
10 years 7.2
Extreme 7.195
396.8
Manager TitleAgeSince
Chief Executive Officer 67 2022-12-14
Director of Finance/CFO 49 2026-03-08
Chief Tech/Sci/R&D Officer - 2024-12-31
Director TitleAgeSince
Chairman 65 2021-09-28
Director/Board Member 66 2020-04-30
Director/Board Member 66 2021-03-31
Date Insider Type Main position Quantity % Market Cap. Importance
10/12/26 Sell

Chief Technology Officer

-422 0.0017%
9/10/26 Other

Chief Technology Officer

47,500 0.1938%
9/10/26 Sell

Chief Technology Officer

-500 0.0020%
Change 5-day change 1-year change 3-year change Capi.($)
+5.17%+23.56%-30.14%-67.63% 268M
+0.34%-3.03%+37.45%+61.06% 64.14B
+0.98%+2.68%+12.25%+83.90% 55.53B
+1.24%+1.66%+12.91%+105.01% 53.03B
-0.30%-0.45%+27.20%+56.40% 45.99B
-0.17%-2.54%+18.33%+99.65% 42.45B
+1.19%+1.94%+229.77%+942.67% 40.45B
-0.26%-4.20%+10.86%+45.18% 32.25B
-2.08%+44.46%+106.24%+92.57% 34.47B
-2.72%-8.79%+22.58%-5.63% 24.23B
Average +0.32%+5.06%+44.74%+141.32% 39.28B
Weighted average by Cap. +0.06%+3.14%+50.00%+161.89%

Financials

2026 *2027 *
Net sales 11.88K 10.66K 9.85K 8.92K 16.67K 1.13M 16.88K 118K 46.93K 592K 44.58K 43.64K 1.88M 9.88K 8.86K 8.2K 7.42K 13.87K 941K 14.03K 97.99K 39.03K 492K 37.08K 36.29K 1.56M
Net income -174M -156M -145M -131M -245M -16.61B -248M -1.73B -689M -8.69B -654M -641M -27.59B -238M -213M -197M -179M -334M -22.66B -338M -2.36B -940M -11.86B -893M -874M -37.64B
Net Debt -96.99M -87.02M -80.45M -72.86M -136M -9.24B -138M -962M -383M -4.83B -364M -356M -15.35B -28.54M -25.61M -23.68M -21.44M -40.06M -2.72B -40.55M -283M -113M -1.42B -107M -105M -4.52B
Projected Income Statement - Annual - Lyell Immunopharma, Inc.
Logo Lyell Immunopharma, Inc.
Lyell Immunopharma, Inc. is a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with hematologic malignancies and solid tumors. The Company’s product candidates include LYL314 and LYL273. Its LYL314, which is in Phase I/II clinical development, is a dual-targeting CD19/CD20 CAR T-cell product candidate designed to increase complete response rates and prolong the duration of response as compared to the approved CD19-targeted CAR T-cell therapies and is under evaluation trial for the treatment of patients with relapsed and/or refractory large B-cell lymphoma. The Company has acquired the global rights to LYL273 (formerly GCC19CART), a novel autologous guanylyl cyclase-C (GCC)-targeted CAR T-cell product candidate for the treatment of metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.
Employees
161
Date Price Change Volume
26-10-29 US$11.59 +6.04% 20,388
26-10-28 US$10.93 +8.00% 156,808
26-10-27 US$10.12 +8.70% 127,907
26-10-26 US$9.310 -0.85% 85,217
26-10-23 US$9.390 +0.11% 101,637
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Lyell Immunopharma, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
10.93USD
Average target price
37.88USD
Spread / Average Target
+246.52%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Lyell Immunopharma, Inc.
  1. Stock Market
  2. Stocks
  3. LYEL Stock